- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01552434
Bevacizumab og Temsirolimus alene eller i kombinasjon med valproinsyre eller cetuximab ved behandling av pasienter med avansert eller metastatisk malignitet eller annen godartet sykdom
En fase I-studie av Bevacizumab, Temsirolimus alene og i kombinasjon med valproinsyre, eller Cetuximab hos pasienter med avansert malignitet og andre indikasjoner
This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body or other disease that is not cancerous. Immunotherapy with bevacizumab and cetuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bevacizumab and temsirolimus work better when given alone or with valproic acid or cetuximab in treating patients with a malignancy or other disease that is not cancerous.
Studieoversikt
Status
Forhold
- Castleman sykdom
- Lymfangioleiomyomatose
- Karsinom i fordøyelsessystemet
- Ondartet neoplasma
- Tilbakevendende brystkarsinom
- Tilbakevendende skjoldbruskkjertelkarsinom
- Metastatisk urotelialt karsinom
- Ondartet kvinnelig reproduksjonssystem neoplasma
- Nevrofibromatose type 2
- Tilbakevendende bløtvevssarkom hos voksne
- Metastatisk malign neoplasma
- Erdheim-Chester sykdom
- Ondartet luftveisneoplasma
- Ondartet thoraxneoplasma
- Stage IV brystkreft AJCC v6 og v7
- Avansert ondartet neoplasma
- Tilbakevendende ondartet neoplasma
- Refraktær ondartet neoplasma
- Stage III brystkreft AJCC v7
- Stage IIIA brystkreft AJCC v7
- Stage IIIB brystkreft AJCC v7
- Stage IIIC brystkreft AJCC v7
- Tilbakevendende bløtvevssarkom fra barndommen
- Mykvevsneoplasma
- Leppe- og munnhulekarsinom
- Ondartet endokrin neoplasma
- Ondartet mannlig reproduksjonssystem neoplasma
- Malignt urinveisneoplasma
- Mesothelial neoplasma
- Tilbakevendende karsinom i fordøyelsessystemet
- Tilbakevendende karsinom i det kvinnelige reproduktive systemet
- Tilbakevendende karsinom i mannlig reproduktiv system
- Tilbakevendende faryngeal karsinom
- Fase III Faryngeal kreft
- Stage IV Faryngeal kreft
- Stage IVA Faryngeal kreft
- Stadium IVB Faryngeal kreft
- Stage IVC Faryngeal kreft
- Skjoldbruskkjertelneoplasma
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of treatment with bevacizumab and temsirolimus in combination and plus valproic acid or cetuximab.
SECONDARY OBJECTIVES:
I. Preliminary descriptive assessment of anti-tumor efficacy of each combination.
II. Preliminary assessment of the pharmacokinetic, pharmacodynamic markers of target inhibition and correlates of response (optional).
OUTLINE: This is a dose-escalation study of bevacizumab and temsirolimus. Patients are assigned to 1 of 3 treatment groups.
GROUP I: Patients receive temsirolimus intravenously (IV) over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22.
GROUP II: Patients receive temsirolimus and bevacizumab as in Group I and valproic acid orally (PO) daily on days 1-7 and 15-21.
GROUP III: Patients receive temsirolimus and bevacizumab as in Group I.
In all groups, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- M D Anderson Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients with advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or have no standard therapy that induces a complete response of at least 10% or improves survival by at least three months; in addition, patients with disease that are "benign" by pathology, but relentlessly progressive, leading to disability, pain, and premature death in the majority of cases (including, but not limited to lymphangioleiomyomatosis [LAM], type 2 neurofibromatosis [NF], Erdheim Chester disease, and Castleman's disease) may also be considered for enrollment
- Patients should be at least four weeks from the last day of therapeutic radiation or cytotoxic chemotherapy or from antibody therapy, or at least five half-lives from non-cytotoxic targeted or biologic therapy; patients may have received palliative radiation immediately before (or during) treatment provided radiation is not to the only target lesion available
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Karnofsky >= 60%
- Lansky performance status of >= 60% for participants 16 years old or younger
- Absolute neutrophil count >= 1,000/mL
- Platelets >= 50,000/mL
- Creatinine =< 3 X upper limit of normal (ULN)
- Total bilirubin =< 3.0
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 X ULN
- Fasting level of total cholesterol of no more than 350 mg/dL
- Triglyceride level of no more than 400 mg/dL
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days after the last dose
- Ability to understand and the willingness to sign a written informed consent document
- Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies
Exclusion Criteria:
- Patients with clinically significant unexplained bleeding within 28 days prior to entering the study
- Uncontrolled systemic vascular hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg on medication)
- Patients with clinically significant cardiovascular disease: History of CVA (cerebrovascular accident) within 6 months, myocardial infarction or unstable angina within 6 months, unstable angina pectoris
- Pregnant or breast-feeding women
- History of hypersensitivity to bevacizumab, murine products, or any component of the formulation
- History of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any component of the formulation
- History of hypersensitivity to cetuximab, murine products, or any component of the formulation
- Patients that are taking cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) inducers and/or inhibitors; if a patient has a history of taking CYP3A4 inducers and/or inhibitors prior to enrollment on the protocol, it is strongly recommended that the patient stops the drug and waits at least 5 half-lives of said drug before initiating therapy on protocol
- Colorectal cancer patients with known v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation (for the arm combining bevacizumab, temsirolimus and cetuximab)
- Patients who have had major surgery within 6 weeks of enrollment in the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Group I (temsirolimus, bevacizumab, cetuximab)
Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given IV
Andre navn:
Optional correlative studies Given IV
Andre navn:
Given IV
Andre navn:
Optional correlative studies |
|
Eksperimentell: Group II (temsirolimus, bevacizumab, valproic acid)
Patients receive temsirolimus and bevacizumab as in Group I and valproic acid PO on days 1-7 and 15-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given IV
Andre navn:
Optional correlative studies Given IV
Andre navn:
Optional correlative studies Given PO
Andre navn:
|
|
Eksperimentell: Group III (temsirolimus, bevacizumab)
Patients receive temsirolimus and bevacizumab as in Group I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given IV
Andre navn:
Optional correlative studies Given IV
Andre navn:
Optional correlative studies |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Dose Limiting Toxicities (DLT)
Tidsramme: First 28-day cycle
|
A dose limiting toxicity (DLT) is defined as a clinically significant adverse event or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications and occurring during the first cycle on study that meets any of the following criteria:
|
First 28-day cycle
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Sarina A Piha-Paul, M.D. Anderson Cancer Center
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26;7(17):23227-38. doi: 10.18632/oncotarget.7594.
- Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist. 2023 Dec 11;28(12):1100-e1292. doi: 10.1093/oncolo/oyad158.
- Piha-Paul SA, Tseng C, Thompson E, Stafford RJ, Le H, Kang L, Fu S, Tsimberidou A, Blumenschein G, Ahnert JR, Slopis JM, Hong D, Naing A, Meric-Bernstam F, Ng CS, Westin S, Sood AK. Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion. Oncologist. 2026 Feb 5;31(3):oyaf413. doi: 10.1093/oncolo/oyaf413.
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Antatt)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Sykdommer i det endokrine systemet
- Munnsykdommer
- Stomatognatiske sykdommer
- Sykdommer i nervesystemet
- Patologiske prosesser
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Mannlige urogenitale sykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Sykdomsattributter
- Genetiske sykdommer, medfødte
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Neoplasmer i hode og nakke
- Nevrodegenerative sykdommer
- Neoplasmer, kjertel og epitel
- Neoplastiske prosesser
- Hudsykdommer
- Bryst sykdommer
- Lymfesykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Karsinom
- Otorhinolaryngologiske sykdommer
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Heredodegenerative lidelser, nervesystemet
- Neoplasmer i nerveskjede
- Neoplastiske syndromer, arvelig
- Nevrokutane syndromer
- Nevroendokrine svulster
- Øresykdommer
- Otorhinolaryngologiske neoplasmer
- Faryngeale sykdommer
- Neoplasmer, bindevev og mykt vev
- Sykdommer i kranienerve
- Skjoldbrusk sykdommer
- Neurom
- Neoplasmer i kranienerve
- Vestibulocochleære nervesykdommer
- Retrokokleære sykdommer
- Histiocytose, ikke-Langerhans-celle
- Nevrofibrom
- Lymfangiomyom
- Perivaskulær epiteloid celle neoplasmer
- Neurom, akustisk
- Neurilemma
- Histiocytose
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Patologiske tilstander, tegn og symptomer
- Hud- og bindevevssykdommer
- Hemic og lymfatiske sykdommer
- Nevrofibromatoser
- Neoplasma, lymfatisk vev
- Neoplasmer
- Tilbakefall
- Brystneoplasmer
- Neoplasma Metastase
- Sarkom
- Urologiske neoplasmer
- Castleman sykdom
- Neoplasmer i munnen
- Karsinom, overgangscelle
- Neoplasmer i skjoldbruskkjertelen
- Lymfangioleiomyomatose
- Nevrofibromatose 2
- Mykvevsneoplasmer
- Faryngeale neoplasmer
- Neoplasmer, mesoteliale
- Erdheim-Chester sykdom
- Neoplasmer i endokrine kjertel
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovelforbindelser
- Organiske kjemikalier
- Fettsyrer
- Lipider
- Syrer, acyklisk
- Karboksylsyrer
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Uorganiske kjemikalier
- Pentansyrer
- Valerater
- Fettsyrer, flyktige
- Makrolider
- Laktoner
- Immunoglobulinisotyper
- Sulfider
- Anioner
- Ioner
- Elektrolytter
- Hydrogensulfid
- Bevacizumab
- Cetuximab
- Sirolimus
- Immunoglobulin G
- Valproinsyre
- Disulfider
- Temsirolimus
Andre studie-ID-numre
- 2012-0061
- 2012-0061 (Annen identifikator: M D Anderson Cancer Center)
- NCI-2012-00347 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .